Immune Thrombocytopenia Associated with Efalizumab Therapy for Psoriasis
Notice bibliographique
Résumé
Letters15 November 2005Immune Thrombocytopenia Associated with Efalizumab Therapy for PsoriasisTheodore E. Warkentin, MD and Paul Kwon, MDTheodore E. Warkentin, MDFrom Hamilton Health Sciences, Hamilton, Ontario L8L 2X2, Canada and Genentech, South San Francisco, CA 94080. and Paul Kwon, MDFrom Hamilton Health Sciences, Hamilton, Ontario L8L 2X2, Canada and Genentech, South San Francisco, CA 94080.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-143-10-200511150-00028 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:Background: Efalizumab is a recombinant humanized anti-CD11a monoclonal IgG1 antibody. Efalizumab recognizes the α-subunit of leukocyte function-associated antigen type 1, thereby blocking interaction between the antigen and intercellular adhesion molecules and associated signaling and T-cell migration (1). The agent is licensed for the treatment of moderate to severe plaque psoriasis (2).Objective: To describe the frequency, clinical features, and response to treatment of putative immune-mediated thrombocytopenia during efalizumab treatment.Methods: During the efalizumab clinical development program, 2762 patients were treated with the drug. We reviewed the case files of all patients with thrombocytopenia (classified by investigators as ...References1. Lebwohl M, Tyring SK, Hamilton TK, Toth D, Glazer S, Tawfik NH, et al. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med. 2003;349:2004-13. [PMID: 14627785] CrossrefMedlineGoogle Scholar2. Efalizumab (Raptiva) for treatment of psoriasis. Med Lett Drugs Ther. 2003;45:97-8. [PMID: 14657802] MedlineGoogle Scholar3. George JN, Raskob GE, Shah SR, Rizvi MA, Hamilton SA, Osborne S, et al. Drug-induced thrombocytopenia: a systematic review of published case reports. Ann Intern Med. 1998;129:886-90. [PMID: 9867731] LinkGoogle Scholar4. Neylon AJ, Saunders PWG, Howard MR, Proctor SJ, Taylor PRA. Clinically significant newly presenting autoimmune thrombocytopenic purpura in adults: a prospective study of a population-based cohort of 245 patients. Br J Haematol. 2003;122:966-74. [PMID: 12956768] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: From Hamilton Health Sciences, Hamilton, Ontario L8L 2X2, Canada and Genentech, South San Francisco, CA 94080.Disclosures: Employment: P. Kwon (Genentech); Consultancies: T.E. Warkentin (Genentech); Stock ownership: P. Kwon (Genentech). PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByPathophysiology and Diagnosis of Drug-Induced Immune ThrombocytopeniaDrug-induced thrombocytopenia: mechanisms and relevance in preclinical safety assessmentDrug-Induced ThrombocytopeniaDrug-Induced Thrombocytopenia: Pathogenesis, Diagnosis and ManagementEfalizumabUnexpected Hematologic Effects of Biotherapeutics in Nonclinical Species and in HumansDrug-Induced ThrombocytopeniaDrug-induced platelet disordersEfalizumabAdverse Drug Reactions Affecting Blood CellsEfalizumab-induced thrombocytopenia: report of relapse after re-administrationThrombocytopenia and Other Hot TopicsDrug-induced immune thrombocytopenia: pathogenesis, diagnosis, and managementThrombocytopenia associated with the use of anti–tumor necrosis factor–α agents for psoriasisLong-term data in the treatment of psoriasisDelayed autoimmune hemolytic anemia in efalizumab-treated psoriasisPancytopénie au cours d'un traitement par efalizumabEfalizumab-induced immune thrombocytopenia during retreatmentEfalizumab: ¿un tratamiento seguro para una enfermedad crónica?Drugs that act on the immune system: cytokines and monoclonal antibodiesFrom the Medical Board of the National Psoriasis Foundation: Monitoring and vaccinations in patients treated with biologics for psoriasisEfalizumab-associated thrombocytopeniaEfalizumabCurrent advancements in the treatment of psoriasis: Immunobiologic agentsBiologic Therapies for Inflammatory Disease 15 November 2005Volume 143, Issue 10Page: 761-763KeywordsClinical trialsCorticosteroid therapyDrug administrationDrug therapyDrugsIdiopathic thrombocytopenic purpuraPathogenesisPatientsPlateletsPsoriasis ePublished: 15 November 2005 Issue Published: 15 November 2005 CopyrightCopyright © 2005 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...
Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.
Comment cette classification a été obtenuedéplier
Prédiction machine sur la base complète
Imitation des enseignantsNi prévalence calibrée, ni vérité terrain. Validation humaine à venir. Le volet Gemma est une étiquette directe du modèle pour chaque travail de la base, lue sur la notice réduite au titre. Le volet Codex est un classifieur appris des 10 348 étiquettes directes de Codex et calibré sur les taux pondérés de l'échantillon; les champs sans appui suffisant ne portent aucun appel Codex. Le mode candidate est l'union des deux volets; le consensus est leur intersection. Ces sorties portent le statut machine_predicted_unvalidated et ne sont pas des étiquettes humaines.
Scores du classifieur distillé par catégorie (deux têtes)
| Catégorie | Codex | Gemma |
|---|---|---|
| Métarecherche | 0,001 | 0,003 |
| Méta-épidémiologie (sens strict) | 0,000 | 0,000 |
| Méta-épidémiologie (sens large) | 0,001 | 0,000 |
| Bibliométrie | 0,001 | 0,001 |
| Études des sciences et des technologies | 0,001 | 0,000 |
| Communication savante | 0,001 | 0,000 |
| Science ouverte | 0,000 | 0,000 |
| Intégrité de la recherche | 0,001 | 0,001 |
| Charge utile insuffisante (le modèle a refusé de juger) | 0,002 | 0,000 |
Scores machine (provisoires)
Les deux têtes enseignantes du modèle étudiant, lues sur ce travail. Un score ordonne la base pour la relecture; il n'affirme jamais une catégorie, et le statut de validation accompagne chaque rangée tel quel.
Scores de référence d'un modèle non mature (critères de maturité non atteints, 7 itérations). Un score ordonne; il n'affirme jamais une catégorie.
score_only:v0-immature-baseline · tel quel depuis la passe de notation : score_only signifie que le nombre peut ordonner les travaux, et qu'aucune étiquette de catégorie n'en découleClassification
machine, non validéePrédiction automatique; un appel candidat d’une seule source (Gemma direct ou Codex distillé), pas un consensus.
Le détail, modèle par modèle et score par score, se trouve en fin de page sous « Comment cette classification a été obtenue ».